Safety Aspects of Immunoadsorption in IgG Removal Using a Single-Use, Multiple-pass Protein A Immunoadsorber (LIGASORB): Clinical Investigation in Healthy Volunteers

Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Sven SüfkeFrank Gebauer

Abstract

Therapeutic apheresis and immunoadsorption are used to deplete efficiently pathogenic autoantibodies in crises in several acute autoimmune driven diseases. This prospective, non-comparative cohort study was conducted at a single study center under standardized conditions in 10 healthy volunteers. Efficient immunoglobulin G (IgG) removal (-86% versus baseline) was achieved after 3 apheresis treatments on 3 consecutive days. The treatments were well tolerated. Safety laboratory parameters did not show unexpected or pathological changes. The effects were transient, with most parameters exhibiting complete recovery between treatments. Minimal complement activation and moderate transient fibrinogen depletion were observed. Immunoadsorption with LIGASORB® provides a safe and effective treatment alternative to TPE in acute episodes of peripheral neurological diseases mediated by pathogenic IgG autoantibodies.

References

Nov 1, 1990·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R M HakimR M Watt
May 4, 1999·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·G A SiamiW J Stone
Feb 9, 2002·Journal of Clinical Apheresis·R Weinstein
May 2, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Rong-Kuo LyuSung-Tsang Hsieh
Oct 6, 2005·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Nikolina Basic-JukicZvonimir Puretic
Aug 28, 2007·Journal of Clinical Apheresis·Douglas SheminMelanie Greenan
May 5, 2010·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Jun-Feng LiuYong Gu
Nov 19, 2011·Journal of Clinical Apheresis·Wolfgang KöhlerReinhard Klingel
Jan 30, 2013·Atherosclerosis. Supplements·Franz HeiglErich Mauch
Jan 30, 2013·Atherosclerosis. Supplements·Michael J KoziolekGerhard A Müller
Oct 18, 2013·QJM : Monthly Journal of the Association of Physicians·T F HiemstraI Schoenmakers
Nov 2, 2013·Clinical Journal of the American Society of Nephrology : CJASN·Mark E Williams, Rasheed A Balogun
Dec 17, 2014·Blood Purification·Patrick M HonoréHerbert D Spapen

❮ Previous
Next ❯

Citations

Jul 2, 2020·Journal of Clinical Medicine·Alexander J DaviesSimon Rinaldi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Antibodies: Complement Activation

The complement system can be activated by antigen-associated antibody. In the classical pathway of complement activation, C1q, C4b, and C3b are all able to bind to the Fc portion of IgG or IgM. Find the latest research on antibodies and complement activation here.

Related Papers

Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis
N Shibuya
Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis
B O Khatri
© 2022 Meta ULC. All rights reserved